Valuation: 4basebio PLC

Market Cap 81.58M 109M 95.59M 88.9M 153M 10.48B 156M 1.06B 412M 5.15B 409M 400M 17.82B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 81.88M 109M 95.95M 89.23M 154M 10.52B 156M 1.06B 414M 5.17B 410M 401M 17.88B EV / Sales 2026 *
29.2x
EV / Sales 2027 * 8.94x
Free-Float
38.72%
Yield 2026 *
-
Yield 2027 * -
Current month+0.96%
3 months+3.96%
6 months-8.70%
Current year-14.63%
1 week 500
Extreme 500
519.75
1 month 500
Extreme 500
550
Current year 420
Extreme 420
630
1 year 420
Extreme 420
1,000
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 2026-02-09
Chief Tech/Sci/R&D Officer - 2025-02-28
Chief Operating Officer - 2026-03-11
Director TitleAgeSince
Director/Board Member 48 2020-12-21
Director/Board Member 33 2024-08-07
Chairman 60 2025-07-07
Date Insider Type Main position Quantity % Market Cap.
5/21/26 Buy

Chief Executive Officer

1,863 0.0120%
2/16/26 Buy

Chief Executive Officer

2,650 0.0171%
2/11/26 Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-45.88%-7.08% 109M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.20%+0.75%+43.77%+94.65% 24.54B
Weighted average by Cap. +0.48%+0.91%+75.26%+136.58%

Financials

2026 *2027 *
Net sales 2.8M 3.74M 3.28M 3.05M 5.26M 360M 5.34M 36.23M 14.16M 177M 14.02M 13.72M 612M 12M 16.01M 14.06M 13.08M 22.55M 1.54B 22.89M 155M 60.67M 758M 60.1M 58.81M 2.62B
Net income -17.1M -22.81M -20.04M -18.63M -32.13M -2.2B -32.62M -221M -86.45M -1.08B -85.65M -83.8M -3.73B -
Net Debt 300K 400K 352K 327K 564K 38.55M 572K 3.88M 1.52M 18.95M 1.5M 1.47M 65.52M 25.7M 34.29M 30.12M 28.01M 48.29M 3.3B 49.03M 333M 130M 1.62B 129M 126M 5.61B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
26-07-24 GBX 525.00 0.00% 9
26-07-23 GBX 525.00 0.00% 324
26-07-22 GBX 525.00 0.00% 248
26-07-21 GBX 525.00 0.00% 22
26-07-20 GBX 525.00 0.00% 347
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.250GBP
Average target price
16.00GBP
Spread / Average Target
+204.76%

Annual profits - Rate of surprise